Contineum Therapeutics, Inc. (NASDAQ:CTNM) Shares Purchased by Barclays PLC

Barclays PLC increased its holdings in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 248.6% in the third quarter, Holdings Channel reports. The firm owned 8,308 shares of the company’s stock after buying an additional 5,925 shares during the quarter. Barclays PLC’s holdings in Contineum Therapeutics were worth $158,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. Sandia Investment Management LP purchased a new position in shares of Contineum Therapeutics in the 2nd quarter valued at about $88,000. Rhumbline Advisers purchased a new position in shares of Contineum Therapeutics in the 2nd quarter valued at about $118,000. BNP Paribas Financial Markets increased its holdings in shares of Contineum Therapeutics by 1,248.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company’s stock valued at $129,000 after purchasing an additional 6,243 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Contineum Therapeutics in the 2nd quarter valued at about $356,000. Finally, Driehaus Capital Management LLC purchased a new position in shares of Contineum Therapeutics in the 2nd quarter valued at about $1,174,000.

Analysts Set New Price Targets

Several equities analysts have weighed in on CTNM shares. Baird R W upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Robert W. Baird assumed coverage on shares of Contineum Therapeutics in a research report on Tuesday, October 22nd. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of Contineum Therapeutics in a research report on Thursday, January 9th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $29.25.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $11.21 on Thursday. The company has a fifty day simple moving average of $14.24 and a 200 day simple moving average of $16.95. Contineum Therapeutics, Inc. has a 12-month low of $11.15 and a 12-month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last released its earnings results on Wednesday, November 6th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.01. As a group, analysts expect that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).